Phase 4 Study to Test Switch From Anti-CD20 Therapy to Ozanimod in Stable MS

The study will track patients over 36 months and use T2 lesion count and the number of serious infections as primary endpoints, with secondary endpoints including adverse events, relapse rates, and the achievement of no evidence of disease activity.:

Source: Neurology Read More